Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
BIOJECT MEDICAL TECHNOLOGIES INC (BJCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/27/2015 |
8-K
| Quarterly results |
| 08/14/2015 |
8-K
| Quarterly results |
| 05/15/2015 |
8-K
| Quarterly results |
| 04/01/2015 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Departure of Directors or Certain ...|
Docs:
|
"Note from Company to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $116,636",
"Security Agreement dated March 3, 2015, by and among the Company, Bioject Inc. and Mark A. Logomasini & Associates, Inc. SEP Fund",
"Note from the Company to John E. Anderson in the principal sum of $50,000",
"Note from the Company to Sam Bhattacharjee in the principal sum of $50,000",
"Note from the Company to Sam Bhattacharjee in the principal sum of $50,000",
"Note from the Company to Life Sciences Opportunities Fund II, LP in the principal sum of $45,552",
"Note from the Company to Life Sciences Opportunities Fund (Institutional) II. LP in the principal sum of $254,448",
"Security Agreement dated February 18, 2015, by and among the Company, Bioject Inc., Life Sciences Opportunities Fund II, LP and Life Sciences Opportunities Fund (Institutional) II, LP",
"BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2014 FINANCIAL RESULTS Tigard, OR - March 25, 2015 - Bioject Medical Technologies Inc. , a developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the year and quarter ended December 31, 2014. The financial results are unaudited and actual results may vary. 12 Months Ended December 31, 2014" |
|
| 02/13/2015 |
SC 13D/A
| LIFE SCIENCES OPPORTUNITIES FUND II LP reports a 67.6% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 11/12/2014 |
8-K
| Quarterly results |
| 08/15/2014 |
8-K
| Quarterly results|
Docs:
|
"Form of Note from Bioject to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $100,000",
"For value received,",
"SECURITY AGREEMENT This Security Agreement is made June 25, 2014 by and among Bioject Medical Technologies Inc. and its wholly owned subsidiary Bioject Inc. , each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 , and Mark A. Logomasini & Associates, Inc. SEP Fund and Amir Ness, the holders of the Company's Senior Secured Bridge Promissory Notes in the amounts of $100,000 and $50,000, respectively, dated June 23, 2014 and June 25, 2014, respectively and with the addresses set forth on the signature page hereto . RECITALS The Noteholders have agreed to make a secured loan to the Company, evidenced by the Notes, are secured by all the accounts receivable from Ferring Pharmaceuticals to the Company, whether presently existing or hereafter acquire...",
"BIOJECT REPORTS UNAUDITED SECOND QUARTER 2014 FINANCIAL RESULTS" |
|
| 07/31/2014 |
SC 13D
| FLYNN EDWARD L reports a 14.8% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 07/03/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/03/2014 |
SC 13D
| Logomasini Mark reports a 14.5% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 06/03/2014 |
SC 13D/A
| LIFE SCIENCES OPPORTUNITIES FUND II LP reports a 50.6% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 05/15/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/20/2014 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 10/01/2013 |
8-K
| Quarterly results |
| 08/30/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/17/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/20/2013 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"LOGOMASINI EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is dated February 15, 2013 between: BIOJECT MEDICAL TECHNOLOGIES INC. , a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 BIOJECT INC . , a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 AND: Mark Logomasini, having an office address at 26212 Dimension Drive, Suite 260, Lake Forest, CA 92630 . RECITALS WHEREAS, the Executive has heretofore been employed by the Company. WHEREAS, the Company and Executive desire to set forth in this agreement the terms and conditions of Executive's employment with the Company. NOW, TH..." |
|
| 02/19/2013 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities |
| 02/15/2013 |
SC 13D/A
| LIFE SCIENCES OPPORTUNITIES FUND II LP reports a 59.5% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 11/15/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 08/15/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 06/01/2012 |
RW
| Form RW - Registration Withdrawal Request |
| 05/16/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 04/03/2012 |
8-K
| Form 8-K - Current report |
| 11/10/2011 |
10-Q
| Quarterly Report for the period ended September 30, 2011 |
| 11/08/2011 |
8-K
| Form 8-K - Current report |
| 10/05/2011 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/30/2011 |
8-K
| Form 8-K - Current report |
| 08/12/2011 |
10-Q
| Quarterly Report for the period ended June 30, 2011 |
| 08/10/2011 |
8-K
| Quarterly results|
Docs:
|
"BIOJECT REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS Revenue Doubles Over Second Quarter 2010 PORTLAND, OR, August 10, 2011 - Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, today reported financial results for the second quarter ended June 30, 2011. Bioject reported revenues of $2.4 million for the quarter ended June 30, 2011, compared to revenues of $1.2 million in the comparable 2010 period. Product sales were $2.2 million in the 2011 period compared to $1.0 million in the comparable 2010 period. License and technology fees were $209,000 for the quarter ended June 30, 2011, compared to $117,000 in the comparable 2010 period. The Company reported operating income of $276,000 in the second quarter of 2011 compared to an operating loss of $593..." |
|
| 08/10/2011 |
BW
| Bioject Reports Second Quarter 2011 Financial Results |
| 07/18/2011 |
D
| Form D - Notice of Exempt Offering of Securities |
| 07/01/2011 |
8-K
| Form 8-K - Current report |
|
|
|